AVAX Technologies, Inc.
OTC: AVXT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Adele Sommerfeld
- Employees
- 9
- Headquarters
- Philadelphia, United States
- IPO year
- 1997
- Market cap
- $6.9K
- Website
- https://www.avax-tech.com
Loading AVXT…
Loading profile data…Frequently asked questions about AVXT
What does AVAX Technologies, Inc. (AVXT) do?
AVAX Technologies, Inc. is an emerging biopharmaceutical company focused on pioneering autologous cell vaccine methods for cancer therapy. Its pipeline includes lead candidates M-VAX, for melanoma, and O-VAX, targeting ovarian cancer, both of which have successfully concluded Phase II clinical trials. The firm is also developing LungVax, a poten...
Where does AVXT trade?
AVAX Technologies, Inc. (AVXT) trades on the Other OTC.
What sector is AVXT in?
AVAX Technologies, Inc. (AVXT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of AVAX Technologies, Inc.?
Adele Sommerfeld is the chief executive officer of AVAX Technologies, Inc. (AVXT).
Where is AVAX Technologies, Inc. headquartered?
AVAX Technologies, Inc. is headquartered in United States.
Does AVXT pay a dividend?
AVAX Technologies, Inc. (AVXT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AVXT go public?
AVAX Technologies, Inc. (AVXT) completed its initial public offering in 1997.